California Public Employees Retirement System Sells 7,649 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

California Public Employees Retirement System lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 204,132 shares of the biopharmaceutical company’s stock after selling 7,649 shares during the period. California Public Employees Retirement System’s holdings in Alnylam Pharmaceuticals were worth $48,034,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of ALNY. Larson Financial Group LLC raised its stake in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $33,000. OFI Invest Asset Management bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $35,000. Versant Capital Management Inc grew its position in Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 83 shares in the last quarter. Finally, Quantbot Technologies LP increased its stake in Alnylam Pharmaceuticals by 1,754.5% in the third quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 193 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the sale, the executive vice president now owns 14,321 shares in the company, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ALNY shares. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $280.00 to $328.00 in a report on Monday, March 24th. Redburn Atlantic started coverage on Alnylam Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $353.00 target price for the company. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Finally, Sanford C. Bernstein reduced their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $316.25.

Alnylam Pharmaceuticals Trading Down 5.3 %

Shares of ALNY opened at $255.76 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The firm has a market capitalization of $33.27 billion, a price-to-earnings ratio of -117.86 and a beta of 0.39. The firm’s 50-day moving average price is $260.15 and its 200-day moving average price is $260.51. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.